{
    "clinical_study": {
        "@rank": "9929", 
        "arm_group": {
            "arm_group_label": "OX219", 
            "arm_group_type": "Other", 
            "description": "Week 1-24 OX219 buprenorphine/naloxone sublingual tablet (open-label)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess treatment efficacy and adherence of OX219\n      (Buprenorphine/Naloxone)."
        }, 
        "brief_title": "Follow up Study to Assess Safety, Treatment Efficacy and Adherence of OX219 (Buprenorphine/Naloxone).", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Opioid Dependence, on Agonist Therapy", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "detailed_description": {
            "textblock": "A multi-center-, open-label-, uncontrolled-, single armed-, 24-week, follow-up study to\n      assess safety, efficacy and treatment adherence for maintenance treatment of opioid\n      dependence with OX219.\n\n      Only patients from studies; OX219-006 or OX219-007 is permitted to participate\n\n      Total study treatment 24 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          1. Signed informed consent form (ICF).\n\n          2. Patient has completed the OX219-006 or the OX219-007 study.\n\n          3. Female subjects of child bearing potential who use a reliable method of contraception\n             (e.g. hormonal, condom with spermicide, IUD) during the previous OX219-006 or\n             OX219-007 studies and during the duration of the OX219-008 study. Females of nonchild\n             bearing potential who are either surgically sterile (hysterectomy, bilateral\n             oophorectomy, bilateral salpingectomy, tubal ligation), or post-menopausal as defined\n             by being at least 50 years of age and having had an absence of menses for at least 2\n             years are also allowed.\n\n        Exclusion criteria\n\n          1. Females who are pregnant (positive pregnancy test) or lactating, or planning to be\n             pregnant during study.\n\n          2. Participants who are unwilling or unable to comply with the requirements of the\n             protocol (e.g., pending incarceration) or are in a situation or condition that, in\n             the opinion of the investigator, may interfere with participation in the study.\n\n          3. Participants who are participating in any other clinical study in which medication(s)\n             are being delivered.\n\n          4. Participants with any known allergy or sensitivity or intolerance to BUP, NAL or any\n             related drug, or history of any drug hypersensitivity or intolerance which in the\n             opinion of the investigator, would compromise the safety of the subject or the study.\n\n          5. Participations with a contra-indicated serious medical condition.\n\n          6. Participants who are at suicidal risk as determined by meeting any of the following:\n             history of suicidal ideation \u2264 3 months prior to baseline with a score of 4 (intent\n             to act) or 5 (specify plan and intent) on the C-SSRS; history of suicidal behavior\n             (actual attempt, interrupted attempt, aborted attempt, and/or preparatory\n             acts/behavior) on the C-SSRS."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "700", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903005", 
            "org_study_id": "OX219-008"
        }, 
        "intervention": {
            "arm_group_label": "OX219", 
            "description": "OX219 buprenorphine/naloxone sublingual tablets", 
            "intervention_name": "buprenorphine/naloxone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Naloxone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Opioid, Dependence, agonist, Buprenorphine, Naloxone", 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Jefferson County", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston, Marion", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maricopa", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles County", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego County", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Broward County", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia County", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duval County", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greater Metro Orlando area", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville Metropolitan area", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami-Dade County", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osceola County", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palm Beach County", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "DeKalb County", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicagoland", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore county", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol County", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rankin", 
                        "country": "United States", 
                        "state": "Mississippi"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis Metro Area", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warren County", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma County", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland metropolitan area", 
                        "country": "United States", 
                        "state": "Oregon"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Delaware County", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia County", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston County", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake County", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Benton County", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Open-label, 24-week, Follow-up Study to Assess Safety, Efficacy and Treatment Adherence for Maintenance Treatment of Opioid Dependence With OX219", 
        "overall_official": {
            "affiliation": "TRY Research, 406 Lake Howell Road, Maitland, Florida 32751", 
            "last_name": "Kent Hoffman", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Reported Adverse Events", 
                "measure": "To assess the safety and tolerability  of OX219(AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Blood pressure and pulse rate", 
                "measure": "To assess the safety and tolerability of OX219 (Vital Signs)", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Urine and blood samples (clinical chemistry and hematology)", 
                "measure": "To assess the safety and tolerability of OX219 (Safety laboratory tests)", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Assess suicidal ideation/behavior with Columbia Suicidal Severity Rating Scale (C-SSRS)", 
                "measure": "To assess the safety and tolerability of OX219 (C-SSRS)", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Visual examine of the mouth to check for any local irritation.", 
                "measure": "To assess the safety and tolerability of OX219 (Local tolerability assessments)", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903005"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Scale for assessment of opioid withdrawal symptoms by clinician", 
                "measure": "Clinical Opiate Withdrawal Scale score (COWS)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Scale for assessment of opioid withdrawal symptoms by subject", 
                "measure": "Subjective Opiate Withdrawal Scale score (SOWS)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Scale for assessment of treatment effects of opioid cravings", 
                "measure": "Craving VAS", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Screen for illicit drugs/opioids/buprenorphine", 
                "measure": "Urine drug screen (UDS) and/or urine dipstick", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Patient assessment of treatment effects on illicit drug use", 
                "measure": "Self report of substance use/opioid use", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "To assess treatment effects on addiction severity.", 
                "measure": "Addiction Severity Index - Lite (ASI-Lite)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Patient assessment of improvement/deterioration of opioid dependence severity.", 
                "measure": "Patient Global Impression of Improvement (PGI-I)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Clinician assessment of opioid dependence severity.", 
                "measure": "Clinical Global Impression of Severity (CGI-S)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Clinician assessment of improvement/deterioration of opioid dependence severity.", 
                "measure": "Clinical Global Impression of Improvement (CGI-I)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Recording of dose administrations", 
                "measure": "To evaluate retention in treatment during study period", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Assessment of concomitant pain scale (numerical rating scale [NRS])", 
                "measure": "Pain Numerical rating scale (NRS)", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "To assess the patient perspective on constipation symptoms", 
                "measure": "Patient Assessment of Constipation Symptoms (PAC-SYM)", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Patient general quality of life questionnaire", 
                "measure": "SF-36 ratings", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Patient questionnaire to evaluate the influence of opioid dependence on work capacity / other activities", 
                "measure": "Work productivity/activity impairment: Specific health problem questionnaire (WPAI:SHP)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }, 
            {
                "description": "Patient reported intake confirmed by drug accountability.", 
                "measure": "To assess treatment compliance", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of an expected average of 24 weeks"
            }
        ], 
        "source": "Orexo AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Orexo AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}